BB-1701 has survived Eisai’s decision not to option the HER2-directed antibody-drug conjugate. | BB-1701 has survived Eisai’s ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan Earthquake and the Fukushima Daiichi nuclear disaster. Fourteen years later ...

This was a significant finding compared to the 71.8% growth inhibition with the experimental HER3-targeting ADC, patritumab deruxtecan, which is currently being developed by Merck (NSE:PROR) and ...

In addition, we continue to develop our HER3 ADC EO-1022 for the treatment of a wide range of HER3-expressing solid tumors and look forward to sharing preclinical data at the AACR Annual Meeting ...

-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction ...